Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of John N.
Noble Capital Markets’ Fifteenth Annual Investor / Equity Conference
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 23, 2019– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that its President and Chief Operating Officer, Julien Pham, MD, MPH, will deliver a presentation about the company’s unique, leading-edge gene therapies and will also participate in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV – Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Florida….
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 3, 2019– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare finance at the Hilton San Francisco Union Square….
Company Placing Priority on Investor Engagement with New Website, Email Updates
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 12, 2018– Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of an innovative corporate website with more robust investor resources, including the company’s presentations, stock charts and integrated quotes, SEC filings, news, media coverage, and tailored email newsletters, among other advanced communication tools….
Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 3, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that its Chairman and Chief Executive Officer, Rodney Varner, will present at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, CA….
AUSTIN, TX, November 29, 2017 – Genprex, Inc., a clinical stage gene therapy company, announced today that is has been selected as a finalist in this year’s Fierce Innovation Awards: Life Sciences Edition brought to you by the publisher of FierceBiotech and FiercePharma.
AUSTIN, Texas–(BUSINESS WIRE)–Nov. 20, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the third quarter ended September 30, 2018 on Form 10-Q with the Securities and Exchange Commission….
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 30, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN, as the Company’s Vice President of Clinical Operations.
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual.
AUSTIN,Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management team will present at the following upcoming investor and industry conferences:
Event: The MicroCap Conference
Date: October 2, 2018
Time: 12:00 PM EDT
Location: New York, NY
Presenter: Rodney Varner, Chairman and CEO
Event: BIO Investor Forum
Date: October 18, 2018
Time: 9:30 AM PDT
Location: San Francisco, CA
Presenter: Dr….